Treatment of paediatric TB: revised WHO guidelines

Area of Science:

• Pediatric Infectious Diseases
• Pharmacology
• Public Health

Background:

• Tuberculosis (TB) treatment in children requires age-specific dosing strategies.
• Previous World Health Organization (WHO) guidelines had established specific dosage ranges for first-line anti-TB drugs.
• Understanding pediatric pharmacokinetics is crucial for optimizing TB therapy.

Purpose of the Study:

• To explain the rationale behind the WHO's recent revisions to first-line anti-tuberculosis drug dosages for children.
• To highlight the increased recommended dosages for key anti-TB medications.
• To address the inclusion of ethambutol for all age groups, including those under five.

Main Methods:

• Review of current scientific literature and WHO guidelines.
• Analysis of pharmacokinetic data comparing children and adults.
• Evaluation of safety and toxicity data for revised pediatric dosages.

Main Results:

• Recommended dosages for isoniazid, rifampicin, pyrazinamide, and ethambutol have been increased for pediatric use.
• Ethambutol is now recommended for children across all age ranges, including those younger than five years.
• Available data in HIV-uninfected children indicate a low risk of toxicity with the revised dosages.

Conclusions:

• The revised pediatric TB drug dosages are based on the principle that children need higher doses than adults for equivalent serum concentrations.
• The updated guidelines aim to improve treatment outcomes for childhood tuberculosis.
• Further research is needed to assess the impact of these higher dosages on clinical response, drug interactions, and toxicity in HIV-infected children.